Search results
Showing 16 to 30 of 39 results for alzheimer's disease
Discontinued Reference number: GID-TA10739
Health Technology Assessment Innovation Laboratory (HTA Lab)
NICE's HTA Lab enables us to develop creative solutions to complex problems in health technology assessment.
In development Reference number: GID-TA11269 Expected publication date: TBC
This indicator covers the percentage of patients with moderate or severe frailty and/or multimorbidity who have received a medication review in the last 12 months which is structured, has considered the use of a recognised tool and taken place as a shared discussion. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM186
Excess winter deaths and illness and the health risks associated with cold homes (NG6)
This guideline covers reducing the health risks (including preventable deaths) associated with living in a cold home. It aims to improve the health and wellbeing of people vulnerable to the cold. Improving the temperature in homes, by improving energy efficiency, may also help reduce unnecessary fuel consumption.
Technology appraisal and highly specialised technologies appeals
Learn about the NICE Technology Appraisal and Highly Specialised Technologies appeals process, including how decisions are made, the criteria for appeals, and the role of the appeal panel in ensuring fair and transparent evaluations of health technologies.
This quality standard covers preventing dementia, and assessment, management and health and social care support for people with dementia. It describes high-quality care in priority areas for improvement.
View quality statements for QS184Show all sections
Sections for QS184
- Quality statements
- Quality statement 1: Raising awareness – health promotion interventions
- Quality statement 2: Diagnosis
- Quality statement 3: Advance care planning
- Quality statement 4: Coordinating care
- Quality statement 5: Activities to promote wellbeing
- Quality statement 6: Managing distress
- Quality statement 7: Supporting carers
This guideline covers oral health, including dental health and daily mouth care, for adults in care homes. The aim is to maintain and improve their oral health and ensure timely access to dental treatment.
Alzheimer's disease (mild to moderate) - donepezil, rivastigmine and galantamine (TA19)
This guidance has been replaced by NICE technology appraisal guidance 111.
Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA111)
This guidance has been updated and replaced by NICE technology appraisal 217.
Rehabilitation for chronic neurological disorders including acquired brain injury (NG252)
This guideline covers rehabilitation in all settings for children, young people and adults with a chronic neurological disorder, neurological impairment or disabling neurological symptoms due to acquired brain injury, acquired spinal cord injury, acquired peripheral nerve disorder, functional neurological disorder or progressive neurological disease.
Show all sections
Sections for NG252
- Overview
- Designing and commissioning rehabilitation services
- Assessing rehabilitation needs and goal setting
- Rehabilitation planning and delivery
- Information, advice and learning as part of rehabilitation
- Rehabilitation to maintain, improve or support function
- Rehabilitation to support education, work, social and leisure activities, relationships and sex
- Terms used in this guideline
Artificial intelligence for analysing CT brain scans (MIB207)
NICE has developed a medtech innovation briefing (MIB) on artificial intelligence for analysing CT brain scans .
Urinary incontinence and pelvic organ prolapse in women: management (NG123)
This guideline covers assessing and managing urinary incontinence and pelvic organ prolapse in women aged 18 and over. It also covers complications associated with mesh surgery for these conditions.
This guideline covers managing COVID-19 in babies, children, young people and adults in community and hospital settings. It includes recommendations on communication, assessment, therapeutics for COVID-19, non-invasive respiratory support, preventing and managing acute complications, and identifying and managing co-infections.
Past technology appraisal appeals and decisions